Fangzhou Inc. (6086.HK) has signed a Memorandum of Understanding with Novo Nordisk (NOVOB.CO,NVO) to collaborate on the management of serious chronic diseases, including diabetes and obesity.
Fangzhou has collaborated with Novo Nordisk, using their knowledge and products for treating diabetes and obesity. Fangzhou will use its smart healthcare systems and strong tech platform to build a complete service that helps people manage their health. This service will offer things like advice on using medicine, reminders to take it, tracking how well it works, and health education. Their goal is to improve the whole process of blood sugar and weight control. Instead of just treating illness, they want to focus more on keeping people healthy and making care easier and better for patients—all in one place.
Looking forward, both companies expect to explore further innovative collaborations in the medical industry's digital transformation, with the goal of benefiting patients with serious chronic diseases and accelerating the achievement of the Healthy China 2030 strategic objectives.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.